Endokrynologia Polska 3/2016-Dear Colleagues, Dear Readers,

LIST DO CZYTELNIKÓW/LETTER TO READERS

Dear Colleagues,
Dear Readers,

We bring you a new issue of “Endokrynologia Polska” and we look forward to well-deserved summer holidays. However, this summer we are going to be busy with the preparations for the biggest scientific event, 21st Congress of the Polish Society of Endocrinology in the International Congress Centre in Katowice on 14–17 September 2016. The Congress shall be accompanied by the 7th National Scientific Conference “Controversy in Neuroendocrine Tumours”, which will start on 14 September 2016. We would like to already invite you to these events to the capital of Silesia.

The Original Paper that opens the 3rd issue of “Endokrynologia Polska” comes from Ankara and is based on the assumption that fibroblast growth factor 21 (FGF21) may be a predictor for the development of type 2 diabetes mellitus (T2DM). Therefore, the Authors analysed FGF 21 levels in normoglycaemic and prediabetic first-degree relatives of patients with T2DM. The association has been confirmed – not only FGF21 levels are higher in first-degree relatives of T2DM patients, but also FGF21 level is strongly associated with obesity and insulin sensitivity.

In the next original paper clinicians from Bydgoszcz suggest that SCORE chart for the European population should be modified so that LDL and non-HDL cholesterol levels are included instead of total cholesterol.

The paper from Silesia is the first trial investigating the impact of age on the effects of hypolipidaemic agents on plasma adipokines. The results obtained indicate that the effect of ezetimibe, but not of simvastatin, on adipokine levels is partially determined by the age of the patient. The paper also contains an important practical tip – favourable effect of ezetimibe alone or in combination with simvastatin on the levels of leptin, adiponectin and hsCRP is more evident in patients aged 51–65 years that in those aged 35–50 years.

The role of adipokines in the development of insulin resistance in patients in prediabetes stage was investigated by clinicians from Edirne who showed that low adipokine levels coexists with or contributes to the development of this condition.

The prospective trial performed in Warsaw in patients with Cushing disease who underwent neurosurgery showed unequivocally that despite early remission of hypercortisolaemia, there was no reduction in the levels of fibrinogen and D-dimers. This is the probable reason of the high risk of thromboembolic events in these patients and an indication to careful postoperative monitoring of patients in the remission phase.

The clinicians from Lodz treated non-functioning pituitary adenomas with somatostatin analogues. These tumours are often diagnosed late as invasive macroadenomas. Recurrences are frequently observed after non-radical surgery and in 50% of cases reoperation in needed. The paper shows that somatostatin analogues stabilize the tumour size in the majority of these patients. Furthermore, the analysis of somatostatin receptor subtypes (which this centre is famous for) suggest introduction of novel broad-spectrum somatostatin analogues.

In the next original paper, also from Lodz centre, the Authors focus on the assessment of the secretion and metabolism of melatonin in perimenopausal women with pronounced weight gain. Maybe in the future melatonin secretion disturbances would be a therapeutic goal for eating disorders in postmenopausal women.

In the last original paper in this issue of EP, this time from Turkey, a difficult and rarely discussed topic has been addressed concerning endocrine disorders in critically ill patients treated in the intensive care unit. This paper may be particularly interesting to endocrinologists performing medical consultation in intensive care unit.

Review article from acknowledged diabetological centre in Silesia discusses the problems of insulin treatment optimization. Maybe soon popular methods of subcutaneous insulin delivery will become a thing of the past.

Case Report presented in this issue of EP comes from Paris and describes a young woman with medullary thyroid cancer with low calcitonin level in whom a recurrence has been confirmed using F-DOPA-PET-CT.

In the Postgraduate Education part, we present a paper from Poznan centre including a review of literature regarding possible diagnostic tools for the diagnosis and follow-up of follicular thyroid cancer metastases. The paper is supplemented and enriched by the description of a typical clinical case.

Finally, I wish you an enjoyable summer holiday and invite you to reading our Journal. We are looking forward to meeting you in Katowice after the holidays.

 

On behalf of the Editorial Board

Beata Kos Kudla

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl